Padilla-Noriega L, Werner-Eckert R, Mackow E R, Gorziglia M, Larralde G, Taniguchi K, Greenberg H B
Division of Gastroenterology, Stanford University School of Medicine, California 94305.
J Clin Microbiol. 1993 Mar;31(3):622-8. doi: 10.1128/jcm.31.3.622-628.1993.
Three human rotavirus (HRV) VP4 serotypes and one subtype have been described on the basis of a fourfold or an eightfold-or-greater difference in neutralization titer when tested with hyperimmune antisera to recombinant VP4 or VP8* (serotypes P1A, P1B, P2, and P3). To start to analyze the antigenic basis underlying serotype specificity, we produced a library of 13 VP4-specific neutralizing monoclonal antibodies (NMAbs) to two HRVs, the serotype P1A strain Wa and the serotype P2 strain ST3, and characterized the reactivity of these NMAbs with a panel of serotypically diverse HRV strains by neutralization assay and enzyme-linked immunosorbent assay (ELISA). We characterized the serotypic specificity of the NMAbs by using a fourfold or an eightfold-or-greater difference in titer against the homologous (i.e., immunogen) and heterologous strains as a criterion for serotype. Some ST3-derived NMAbs reacted specifically with serotype P2 HRVs by ELISA and/or neutralization assay, while some Wa-derived NMAbs reacted specifically by ELISA and/or neutralization assay with some or all serotype P1A HRVs. Other Wa- and ST3-derived NMAbs reacted with some or all serotype P1A and P2 HRV strains by neutralization assay and ELISA. Most NMAbs did not react with serotype P1B or P3 strains. In previous studies, three distinct operationally defined epitopes have been identified on VP4 by examining the reactivity patterns of selected antigenic variants of HRV strain KU. At least one of the NMAbs described here recognizes an epitope unrelated to these previously identified epitopes, since it neutralized both KU and its variants.
根据用重组VP4或VP8*的超免疫抗血清检测时中和效价四倍或八倍及以上的差异,已描述了三种人类轮状病毒(HRV)VP4血清型和一种亚型(血清型P1A、P1B、P2和P3)。为了开始分析血清型特异性的抗原基础,我们制备了针对两种HRV(血清型P1A毒株Wa和血清型P2毒株ST3)的13种VP4特异性中和单克隆抗体(NMAb)文库,并通过中和试验和酶联免疫吸附测定(ELISA)表征了这些NMAb与一组血清型不同的HRV毒株的反应性。我们以针对同源(即免疫原)和异源毒株的效价四倍或八倍及以上的差异作为血清型标准,来表征NMAb的血清型特异性。一些源自ST3的NMAb通过ELISA和/或中和试验与血清型P2 HRV特异性反应,而一些源自Wa的NMAb通过ELISA和/或中和试验与部分或所有血清型P1A HRV特异性反应。其他源自Wa和ST3的NMAb通过中和试验和ELISA与部分或所有血清型P1A和P2 HRV毒株反应。大多数NMAb不与血清型P1B或P3毒株反应。在先前的研究中,通过检查HRV毒株KU的选定抗原变体的反应模式,在VP4上鉴定出了三个不同的操作定义表位。此处描述的至少一种NMAb识别一个与这些先前鉴定的表位无关的表位,因为它能中和KU及其变体。